B-cell lymphoma

Biotech

ASH: Should existing BTKs worry about Lilly's newcomer?

The three existing BTK inhibitors can't be used in patients who've failed one another. But Lilly's pirtobrutinib shows it can.
Angus Liu Dec 12, 2022 5:30pm

FDA lifts clinical hold on Curis' phase 1/2 lymphoma trial

Aug 18, 2022 11:23am

Schrödinger gears up for clinic, eyes 'hundreds' of programs

Jul 8, 2022 10:53am

TeneoTwo, put in play by Amgen, lands $100M AstraZeneca buyout

Jul 5, 2022 7:00am

AbbVie lays down marker in fiercely competitive bispecific niche

Jun 13, 2022 8:25am

Gilead's CD47 trials freed of FDA hold—for the most part

Apr 11, 2022 5:22pm